LOGIN  |  REGISTER
Cue Biopharma

Revvity to Present at Upcoming Investor Conferences

August 21, 2024 | Last Trade: US$118.78 0.47 -0.39

WALTHAM, Mass. / Aug 21, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in September 2024:

2024 Wells Fargo Healthcare Conference – Boston, MA

Wednesday, September 4, 2024
8:45 a.m. ET - Max Krakowiak, senior vice president and chief financial officer

2024 Baird Global Healthcare Conference – New York City, NY

Tuesday, September 10, 2024
12:15 p.m. ET - Steve Willoughby, senior vice president, investor relations, ESG, risk

Attendees will receive an update on the Company and its strategic priorities.

Live audio webcasts will be available on the Events section of the Company’s website. Replays of the presentations will be posted on the Revvity Investor Relations website after the events and will be available for at least 30 days.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB